Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition

Neuropsychopharmacology

Volumn 34, Issue 3, 2009, Pages 634-640

  Miksys, Sharon ^a,b   Tyndale, Rachel F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brain; Cytochromes P450; Drug metabolism; Mechanism based inhibitor; Nicotine

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2B1; METHOXSALEN DERIVATIVE; NICOTINE; SUICIDE SUBSTRATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; IN VIVO CULTURE; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; CELL MEMBRANE; CYTOCHROME P-450 CYP2B1; ENZYME INDUCTION; ENZYME INHIBITORS; FRONTAL LOBE; IMMUNOPRECIPITATION; ISOTOPE LABELING; METHOXSALEN; MICROSOMES, LIVER; NICOTINE; RATS; RATS, WISTAR; TRITIUM;

EID: 58149475254     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.110     Document Type: Article

References (56)

1. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R (2004). Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 19: 614-621.
2. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D (1989). Debrisoquine hydroxylation polymorphism and personality. Lancet 1: 555.
3. Britto MR, Wedlund PJ (1992). Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab Dispos 20: 446-450.
4. Caine SB, Heinrichs SC, Coffin VL, Koob GF (1995). Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res 692: 47-56.
5. Chimbira W, Sweeney BP (2000). The effect of smoking on postoperative nausea and vomiting. Anaesthesia 55: 540-544.
6. Coleman T, Spellman EF, Rostami-Hodjegan A, Lennard MS, Tucker GT (2000). The 1′-hydroxylation of Rac-bufuralol by rat brain microsomes. Drug Metab Dispos 28: 1094-1099.
7. Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD (2004). Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann Neurol 55: 897.
8. Desrochers M, Christou M, Jefcoate C, Belzil A, Anderson A (1996). New proteins in the rat CYP2B subfamily: presence in liver microsomes of the constitutive CYP2B3 protein and the phenobarbital-inducible protein product of alternatively spliced CYP2B2 mRNA. Biochem Pharmacol 52: 1311-1319.
9. Dorado P, Penas-Lledo EM, Llerena A (2007). CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 8: 1597-1608.
10. Ekins S, Wrighton SA (1999). The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31: 719-754.
11. Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Amouyel P et al (2004). CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann Neurol 55: 430-434.
12. Forsyth CS, Chambers JE (1989). Activation and degradation of the phosphorothionate insecticides parathion and EPN by rat brain. Biochem Pharmacol 38: 1597-1603.
13. Fradette C, Yamaguchi N, Du Souich P (2004). 5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide. Br J Pharmacol 141: 407-414.
14. Galanaud JP, Elbaz A, Clavel J, Vidal JS, Correze JR, Alperovitch A et al (2005). Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. Mov Disord 20: 181-189.
15. Gervasini G, Carrillo JA, Benitez J (2004). Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin Pharmacokinet 43: 693-706.
16. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V et al (1999). Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9: 295-306.
17. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC et al (1997). Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27: 111-125.
18. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL et al (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14: 225-238.
19. Hiroi T, Imaoka S, Funae Y (1998). Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249: 838-843.
20. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y (2001). Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142: 3901-3908.
21. Ishii G, Suzuki A, Oshino S, Shiraishi H, Otani K (2007). CYP2C19 polymorphism affects personality traits of Japanese females. Neurosci Lett 411: 77-80.
22. Kirchheiner J, Lang U, Stamm T, Sander T, Gallinat J (2006). Association of CYP2D6 genotypes and personality traits in healthy individuals. J Clin Psychopharmacol 26: 440-442.
23. Koenigs LL, Trager WF (1998). Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry 37: 13184-13193.
24. Lieber CS (1999). Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol Clin Exp Res 23: 991-1007.
25. Lin LY, Kumagai Y, Cho AK (1992). Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy) methamphetamine by rat brain microsomes. Chem Res Toxicol 5: 401-406.
26. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L (1993). Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 87: 23-28.
27. Lysakowski C, Dumont L, Czarnetzki C, Bertrand D, Tassonyi E, Tramer MR (2006). The effect of cigarette smoking on the hypnotic efficacy of propofol. Anaesthesia 61: 826-831.
28. McCann SJ, Pond SM, James KM, Le Couteur DG (1997). The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 153: 50-53.
29. Meyer RP, Gehlhaus M, Knoth R, Volk B (2007). Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 8: 297-306.
30. Meyer RP, Lindberg RL, Hoffmann F, Meyer UA (2005). Cytosolic persistence of mouse brain CYP1A1 in chronic heme deficiency. Biol Chem 386: 1157-1164.
31. Meyer RP, Podvinec M, Meyer UA (2002). Cytochrome P450 CYP1A1 accumulates in the cytosol of kidney and brain and is activated by heme. Mol Pharmacol 62: 1061-1067.
32. Michels R, Marzuk PM (1993). Progress in psychiatry (1). N Engl J Med 329: 552-560.
33. Miksys S, Hoffmann E, Tyndale RF (2000). Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 59: 1501-1511.
34. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF (2003). Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45: 122-132.
35. Miksys SL, Tyndale RF (2002). Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 27: 406-415.
36. Miksys S, Tyndale RF (2004). The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 36: 313-333.
37. Miksys S, Tyndale RF (2006). Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl 70: 177-180.
38. Narimatsu S, Yamamoto S, Koitabashi T, Kato R, Masubuchi Y, Suzuki T et al (1999). Biphasic kinetics of imipramine Noxidation in rat brain microsomes. Biol Pharm Bull 22: 253-256.
39. Niwa T, Hiroi T, Tsuzuki D, Yamamoto S, Narimatsu S, Fukuda T et al (2004). Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res 129: 117-123.
40. Ohe T, Hirobe M, Mashino T (2000). Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos 28: 110-112.
41. Paxino G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. 2nd edn, Academic Press: San Diego.
42. Schoedel KA, Sellers EM, Tyndale RF (2001). Induction of CYP2B1/ 2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem Pharmacol 62: 1025-1036.
43. Seliskar M, Rozman D (2007). Mammalian cytochromes P450 - importance of tissue specificity. Biochim Biophys Acta 1770: 458-466.
44. Suzuki T, Fujita S, Narimatsu S, Masubuchi Y, Tachibana M, Ohta S et al (1992). Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetra-hydroisoquinoline in rat liver microsomes. FASEB J 6: 771-776.
45. Tyndale RF, Li Y, Li N-Y, Messina E, Miksys S, Sellers EM (1999). Characterization of cytochrome P-450 2D1 activity in rat brain; high-affinity kinetics for dextromethorphan. Drug Metab Dispos 27: 924-930.
46. Upadhya SC, Chinta SJ, Pai HV, Boyd MR, Ravindranath V (2002). Toxicological consequences of differential regulation of cytochrome p450 isoforms in rat brain regions by phenobarbital. Arch Biochem Biophys 399: 56-65.
47. Vaglini F, Pardini C, Viaggi C, Bartoli C, Dinucci D, Corsini GU (2004). Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced mouse model of Parkinson's disease. J Neurochem 91: 285-298.
48. Viaggi C, Vaglini F, Pardini C, Sgado P, Caramelli A, Corsini GU (2007). CYP 2E1 mutant mice are resistant to DDC-induced enhancement of MPTP toxicity. J Neural Transm Suppl 159-163.
49. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C et al (2000). Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 855: 235-243.
50. Waxman DJ, Walsh C (1982). Phenobarbital-induced rat liver cytochrome P-450Purification and characterization of two closely related isozymic forms. J Biol Chem 257: 10446-10457.
51. Yanev S, Kent UM, Pandova B, Hollenberg PF (1999). Selective mechanism-based inactivation of cytochromes P-450 2B1 and P-450 2B6 by a series of xanthates. Drug Metab Dispos 27: 600-604.
52. Yanev SG, Kent UM, Roberts ES, Ballou DP, Hollenberg PF (2000). Mechanistic studies of cytochrome P450 2B1 inactivation by xanthates. Arch Biochem Biophys 378: 157-166.
53. Yasui-Furukori N, Kaneda A, Iwashima K, Saito M, Nakagami T, Tsuchimine S et al (2007). Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese. Am J Med Genet B Neuropsychiatr Genet 144: 724-727.
54. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ (2003a). Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13: 173-181.
55. Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ (2003b). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13: 307-319.
56. Zanger UM, Raimundo S, Eichelbaum M (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369: 23-37.